This week's episode covers the first FDA-approved ingestible gas-sensing capsule, AI-powered endoscopy with spatial computing, promising Crohn's disease therapeutics, and important regulatory updates affecting clinical practice.

Revolutionary Diagnostic Technology (00:00 - 01:20)

  • Atmo Biosciences FDA Clearance: First ingestible gas-sensing capsule for gut motility disorders
  • Eliminates need for gastric scintigraphy and radio-opaque marker studies
  • Validated in 209-subject pivotal clinical study across 12 sites
  • Available July 2025

AI and Spatial Computing in Endoscopy (01:20 - 02:33)

  • Cosmo Pharmaceuticals + Apple Vision Pro: First clinical study combining AI endoscopy with spatial computing
  • GI Genius AI system integration with Apple Vision Pro headset
  • 14.4% increase in adenoma detection rates
  • Study begins July 2025 at Rush University Medical Center (Dr. Irving Waxman)
  • Fujifilm EC-860P: New slim colonoscope with enhanced imaging capabilities

Clinical Trial Breakthroughs (02:33 - 03:59)

  • Tulisokibart for Crohn's Disease: APOLLO-CD trial results
  • 50% clinical remission vs. 16% historical controls
  • TL1A protein targeting with precision medicine approach
  • Geneoscopy ColoSense: Real-world screening performance data
  • 14% reduction in CRC deaths vs. FIT testing
  • 86% reduction vs. blood-based tests

Regulatory Updates and Quality Concerns (03:59 - 05:38)

  • FDA Import Alert - Olympus: Restrictions on Aizu facility devices
  • Affects bronchoscopes, laparoscopes, ureterorenoscopes
  • Quality system violations and compliance issues
  • Nitinotes EndoZip: FDA IDE approval for automated ESG platform
  • 184-patient pivotal trial across 10 US sites

Professional Guidelines and Market Consolidation (05:38 - 06:58)

  • ACG/WGO H. pylori Guidelines: Updated treatment recommendations
  • Emphasis on clarithromycin resistance testing
  • AGA Crohn's Disease Guidelines: Public comment period through July 20, 2025
  • Torrent-JB Pharmaceuticals: $3.01 billion acquisition

Clinical Implications and Future Outlook (06:58 - 08:22)

  • Integration recommendations for clinical practice
  • Convergence of AI, spatial computing, and precision medicine
  • Future of gastroenterology practice


Published Research

  1. "Tulisokibart for Crohn's Disease: APOLLO-CD Trial Results"
    • The Lancet Gastroenterology & Hepatology
    • 50% clinical remission rate in moderate-to-severe Crohn's disease
    • Cedars-Sinai study led by Dr. Dermot McGovern
  2. "ColoSense Real-World Screening Impact Study"
    • Clinical Gastroenterology and Hepatology
    • 10-year Markov modeling study
    • Superior performance vs. FIT and blood-based tests
  3. "Atmo Biosciences Gas-Sensing Capsule Validation Study"
    • Pivotal clinical study: 209 subjects across 12 sites (11 US, 1 Australia)
    • FDA 510(k) clearance for gut motility disorders

Clinical Trials in Progress

  • Cosmo Pharmaceuticals AI + Apple Vision Pro Study
    • Rush University Medical Center
    • Principal Investigator: Dr. Irving Waxman
    • Study initiation: July 2025
  • Nitinotes EndoZip Pivotal Trial
    • 184 patients across 10 US sites
    • Randomized controlled trial vs. FDA-approved device
    • Patient enrollment: Q3 2025


https://www.gastroendopod.com

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Gastroenterology and Endoscopy. Innehållet i podden är skapat av Gastroenterology and Endoscopy och inte av, eller tillsammans med, Poddtoppen.